Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
World J Gastroenterol ; 13(47): 6439-40, 2007 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-18081237

RESUMO

We report a case of decompensated porto-pulmonary hypertension closely associated with the development of intra-portocaval shunt thrombosis. A woman with Laennec's cirrhosis was hospitalized because of severe dyspnea and edema. She underwent surgical portocaval anastomosis ten years ago. Imaging studies showed massive intra-shunt thrombosis, portal hypertension, ascites, pleuro-pericardial effusions and enlargement of right cardiac cavities. Cardiac catheterization allowed to rule out coronary and left-sided heart abnormalities and led to the diagnosis of pre-capillary pulmonary hypertension. Antithrombotic treatment with low molecular weight heparin was instituted. The management also included ACE inhibitors, spironolactone, low-salt diet and lactulose. The patient was discharged and three months later we observed the disappearance of edema, ascites and pleuro-pericardial effusions, a marked body weight reduction and improved dyspnea and liver function tests. A possible link between the development of intra-shunt thrombosis and clinical decompensation in our patient was hypothesized. In fact, it has been demonstrated that the increased portal pressure, caused by occlusion of portosystemic shunt, reduces renal plasma flow and increases systemic endothelin-1 concentration. In our patient the disappearance of edematous state and improved dyspnea observed after recanalization of the shunt strongly support this hypothesis.


Assuntos
Hipertensão Portal/etiologia , Hipertensão Pulmonar/etiologia , Cirrose Hepática/cirurgia , Derivação Portossistêmica Cirúrgica/efeitos adversos , Trombose Venosa/complicações , Idoso , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Dieta Hipossódica , Diuréticos/uso terapêutico , Quimioterapia Combinada , Dispneia/etiologia , Edema/etiologia , Feminino , Fibrinolíticos/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Hipertensão Portal/complicações , Hipertensão Portal/tratamento farmacológico , Hipertensão Portal/fisiopatologia , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/fisiopatologia , Lactulose/uso terapêutico , Pressão na Veia Porta , Espironolactona/uso terapêutico , Resultado do Tratamento , Vasodilatadores/uso terapêutico , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia , Trombose Venosa/fisiopatologia
3.
J Chemother ; 29(6): 376-379, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28198656

RESUMO

Candida parapsilosis may be responsible for bloodstream infections (BSI) and it is characterised by an increased incidence of fluconazole resistance. A 75-year old woman with severe comorbidities received the insertion of a peripherally inserted central venous catheter. Fluconazole did not prevent a C. parapsilosis BSI hence caspofungin was started after a nephrotoxic first-line treatment with amphotericin B. The ratio of peak plasma concentration over the minimum inhibitory concentration (Cmax/MIC) was adopted to maximise efficacy of caspofungin. MIC and plasma Cmax values were obtained by broth microdilution and LC-MS, respectively. Interestingly, daily doses of 1 mg/kg (total daily dose, 50 mg) allowed the achievement of Cmax/MIC values > 10. The optimised regimen was safe and effective, leading to negative blood culture at day 8. The patient was discharged home at day 21. Therefore, individualised dosing regimens of caspofungin may be effective and safe even in the case of C. parapsilosis BSI.


Assuntos
Antifúngicos/uso terapêutico , Candidemia/tratamento farmacológico , Infecções Relacionadas a Cateter/tratamento farmacológico , Equinocandinas/uso terapêutico , Lipopeptídeos/uso terapêutico , Idoso , Antifúngicos/farmacocinética , Candida parapsilosis , Caspofungina , Farmacorresistência Fúngica , Equinocandinas/farmacocinética , Feminino , Fluconazol , Humanos , Lipopeptídeos/farmacocinética
4.
Am J Med ; 129(12): 1330.e1-1330.e6, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27452680

RESUMO

BACKGROUND: An increasing number of candidemia episodes has been reported in patients cared for in internal medicine wards. These usually older and frail patients may not be suspected as having candidemia because they lack fever at the onset of the episode. To identify the risk factors associated with the lack of fever at the onset of candidemia (ie, the collection of the first positive blood culture for Candida spp.) in patients cared for in internal medicine wards, we compared 2 group of patients with or without fever. METHODS: We retrospectively review data charts from 3 tertiary care, university hospitals in Italy, comparing patients with or without fever at onset of candidemia. Consecutive candidemic episodes in afebrile patients and matched febrile controls were identified during the 3-year study period. Patient baseline characteristics and several infection-related variables were examined. Random forest analysis was used, given the number of predictors to be considered and the potential complexity of their relations with the onset of fever. RESULTS: We identified 147 candidemic episodes without fever at onset and 147 febrile candidemia episodes. Factors associated with the lack of fever at onset of candidemia were diabetes, Clostridium difficile infection, and a shorter delta time from internal medicine wards admission to the onset of candidemia. The only variable associated with fever was the use of intravascular devices. Quite unexpectedly, antifungal therapy was administered more frequently to patients without fever, and no differences on 30-day mortality rate were documented in the 2 study groups. CONCLUSIONS: Clinicians should be aware that an increasing number of patients with invasive candidiasis cared for in internal medicine wards may lack fever at onset, especially those with diabetes and C. difficile infection. Candidemia should be suspected in patients with afebrile systemic inflammatory response syndrome or in worsening clinical condition: blood cultures should be taken, and a timely and appropriate antifungal therapy should be considered.


Assuntos
Candidemia/diagnóstico , Infecção Hospitalar/diagnóstico , Febre/etiologia , Pacientes Internados/estatística & dados numéricos , Idoso , Temperatura Corporal/fisiologia , Candidemia/epidemiologia , Distribuição de Qui-Quadrado , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Feminino , Febre/diagnóstico , Hospitais de Ensino , Humanos , Medicina Interna , Itália/epidemiologia , Masculino , Estudos Multicêntricos como Assunto , Análise Multivariada , Estudos Retrospectivos , Fatores de Risco , Estatísticas não Paramétricas
5.
Thromb Res ; 116(3): 207-14, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15935829

RESUMO

INTRODUCTION: Insulin resistance, a novel cardiovascular risk factor, is often associated with increased plasminogen activator inhibitor-1 levels and impaired vasodilation. Insulin infusion in the forearm induces plasminogen activator inhibitor-1 and tissue plasminogen activator expression and endothelium-dependent vasodilation in normal subjects. The present study explores the relationship between insulin-induced vasodilatory and fibrinolytic properties of the endothelium in women with polycystic ovary syndrome, frequently affected by insulin resistance and early atherosclerosis. MATERIALS AND METHODS: Metabolic, hormonal and fibrinolytic parameters were evaluated in 64 patients with polycystic ovary syndrome (19 insulin-resistant and 45 insulin-sensitive) and in 25 controls. In 16 women with polycystic ovary syndrome, 8 insulin-resistant and 8 insulin-sensitive, blood flow, plasminogen activator inhibitor-1 and tissue plasminogen activator expression were evaluated during insulin infusion into the forearm. RESULTS: Elevated basal plasminogen activator inhibitor-1 levels were found in women with polycystic ovary syndrome, correlating directly with insulin levels. Plasminogen activator inhibitor-1 expression increased during insulin infusion in all women with polycystic ovary syndrome, but was delayed and sustained in insulin-resistant patients (p<0.01). Vasodilatory response to insulin was blunted (p<0.01) and tissue plasminogen activator expression abolished in insulin-resistant patients (p<0.01). CONCLUSION: Our study demonstrates that women with polycystic ovary syndrome and insulin resistance show a blunted endothelial-dependent vasodilation. The impaired endothelial release of tissue-plasminogen activator and the sustained plasminogen activator inhibitor-1 release during insulin infusion suggest a hypofibrinolytic state in PCOS patients with insulin resistance. This hemodynamic and fibrinolytic derangement may contribute to the pathogenesis of early atherosclerosis in insulin resistance.


Assuntos
Fibrinólise , Resistência à Insulina/fisiologia , Síndrome do Ovário Policístico/metabolismo , Síndrome do Ovário Policístico/fisiopatologia , Vasodilatação , Adulto , Arteriosclerose/etiologia , Velocidade do Fluxo Sanguíneo , Estudos de Casos e Controles , Feminino , Fibrinólise/efeitos dos fármacos , Humanos , Insulina/administração & dosagem , Insulina/farmacologia , Inibidor 1 de Ativador de Plasminogênio/sangue , Ativador de Plasminogênio Tecidual/sangue , Vasodilatação/efeitos dos fármacos
6.
Blood Coagul Fibrinolysis ; 14(1): 19-25, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12544724

RESUMO

A relationship may exist between endothelial-mediated vasodilation and tissue-type plasminogen activator (t-PA) release. However, the existing evidence is mainly based upon exogenous agonist administration, and needs testing under more physiological conditions. We evaluated the link between t-PA, the key fibrinolytic factor in man, and forearm reactive hyperemia, a model of endogenous endothelial-mediated vasodilation, in 13 uncomplicated hypertensive subjects and six elderly hypertensive patients with atherosclerotic peripheral vascular disease and hypercholesterolemia (i.e a group in whom post-ischemic hyperemia was probably defective because of dysfunctional endothelium). To characterize further the phenomenon, 29 additional uncomplicated hypertensive patients underwent intra-arterial drug infusions. Study variables were forearm blood flow (strain-gauge plethysmography), arterial and venous concentrations of t-PA mass concentrations, and calculated net release (forearm plasma flow x veno-arterial differences). Reactive hyperemia was induced by inflating a cuff midway between systolic and diastolic pressure for 10 min; blood and forearm blood flow were sampled before and after cuff release. Post-ischemic t-PA release increased in uncomplicated hypertensives, and did not change in hypercholesterolemic atherosclerotic patients in whom post-ischemic vasodilation was negligible. Local adenosine (n = 9), acetylcholine (n = 12) and bradykinin (n = 8) vasodilated similarly, but only bradykinin increased t-PA release. Thus, reactive hyperemia stimulates t-PA release, and that relationship is altered when endothelium is dysfunctional. Release of t-PA is independent of forearm vasodilatation, adenosine or biological products of muscarinic stimulation and may, perhaps, be related to the activity of the endogenous kininogen/kinin system.


Assuntos
Hiperemia/metabolismo , Hipertensão/fisiopatologia , Ativador de Plasminogênio Tecidual/metabolismo , Acetilcolina/administração & dosagem , Acetilcolina/farmacologia , Adenosina/administração & dosagem , Adenosina/farmacologia , Adulto , Idoso , Bradicinina/administração & dosagem , Bradicinina/farmacologia , Antebraço/irrigação sanguínea , Humanos , Hipercolesterolemia , Hiperemia/fisiopatologia , Hipertensão/metabolismo , Masculino , Pessoa de Meia-Idade , Modelos Cardiovasculares , Doenças Vasculares Periféricas , Ativador de Plasminogênio Tecidual/sangue , Vasodilatação/efeitos dos fármacos , Vasodilatação/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA